Generics turn to legislation to cut through biosimilar woes
Sources say patent thickets and pharmacy benefit managers are making it very difficult for generic pharma firms to compete in the US biosimilar space
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: